Adam Johnson

Adam Johnson

Partner
Adam Johnson
New York
+1 212 459 7072

Adam Johnson is a partner in Goodwin’s Life Sciences and Capital Markets practices. He represents leading financial institutions and companies at all levels of corporate structure. Adam advises clients on investments and accessing capital through initial public offerings, equity financings, secured and unsecured high-yield debt, private capital transactions, and other corporate, finance, and securities matters. Adam’s expertise spans a variety of industries including healthcare and life sciences, technology, entertainment, fintech, and retail and consumer products.

Representative Matters

Adam’s clients include: Anika Therapeutics, Disc Medicine, Esperion Therapeutics, ProMIS, ProQR, Rapid Micro Biosystems, Septerna, and Vivani Medical.

  • Olema Pharmaceuticals in its $250 million PIPE financing 
  • Disc Medicine in its $200 million at-the-market offering
  • The underwriters in Verrica Pharmaceutical’s $32 million registered direct offering*
  • Syneos in its $600 million notes offering*
  • The underwriters and sales agent in CureVac’s $213 million initial public offering, $450 million follow on offering, and $250 million follow-on offering, and $600 million at-the-market offering*
  • Septerna, Inc. in its $288 million upsized initial public offering
  • ProQR Therapeutics in its $63 million follow-on offering and concurrent $12.3 million private placement
  • RA Capital Management in Eliem Therapeutics’ $120 million PIPE financing
  • AVROBIO in its reverse merger with Tectonic Therapeutics and concurrent private placement
  • Disc Medicine in its $178 million follow-on offering
  • Monte Rosa Therapeutics, Inc. in its $100 million public offering
  • Vivani Medical in its $75 million at-the-market offering
  • The exclusive placement agent in Acrivon Therapeutic’s $130 million private placement
  • Akero Therapeutics in connection with its $366.9 million upsized public follow-on offering
  • Vivani Medical in its $15 million registered direct offering
  • BofA Securities and BITG as placement agents in Outlook Therapeutics, Inc.’s $60 million PIPE
  • The underwriters in Acrivon Therapeutics’ $100 million at-the-market offering
  • ProMIS Neurosciences in its $122.7 million PIPE financing and $25 million at-the-market offering
  • Rapid Micro Biosystems in its $10 million at-the-market offering
  • Medicxi Ventures in its purchase of $30 million worth of common stock in Phatham Pharmaceuticals in a secondary sale from Takeda Pharmaceutical Company Limited
  • Evelo Biosciences in its $85 million initial public offering, $50 million at-the-market offering, $45 million follow-on offering, $68 million follow-on offering, $7.5 million private placement, $79 million follow-on offering, and $75 million at-the-market offering*
  • Akebia Therapeutics in its merger with Keryx Biopharmaceuticals*
  • The underwriters in Cara Therapeutics $86 million follow-on offering and $127 million follow-on offering*
  • The underwriters in NewLink Genetics’ $51 million follow-on offering*
  • Atea Pharmaceuticals in its $300 million initial public offering*
  • The underwriters in Sigilon Therapeutics’ $126 million initial public offering*
  • The underwriters in Fusion Pharmaceuticals’ $212.5 million initial public offering*

*Denotes experience prior to joining Goodwin.

  • The dealer manager in WeWork’s exchange offer of $669 million senior notes*
  • Evertec in its $200 million secondary follow-on offering*
  • Silver Lake Partners in its $12.5 billion acquisition and take-private of Qualtrics*
  • Oddity Tech in its $424 million initial public offering*
  • The underwriters in CuriosityStream’s $88 million follow-on offering*
  • The underwriters in Skyward Specialty Insurance’s $134 million initial public offering, $153 million follow-on offering, and $89 million secondary follow-on offering*
  • The underwriters in Strategic Education’s $192 million follow-on offering*
  • The underwriters in CarParts.com’s $64 million follow-on offering*
  • The initial purchasers in Kaiser Aluminum’s $500 million notes offering*
  • The initial purchasers in Icahn Enterprises’ $750 million notes offering, $500 million notes offering, $300 million notes offering, $300 million notes offering, and $500 million notes offering*
  • The initial purchasers in Citadel’s notes offering*
  • UGI International in its $350 million notes offering*
  • LogMeIn in its merger with Citrix’s GetGo subsidiary*
  • Spectrum Equity in its investment in Origami Risk*
  • Harvest Partners in its investment in GPM Investments*
  • Landon Capital in its investment in NSA Industries*
  • The underwriters in a mixed primary and secondary offering of $71.3 million of J. Jill common stock
  • The underwriters in PACS Group $450 million initial public offering and $690 million follow-on offering
  • MeridianLink, Inc. in its $44 million public offering
  • Shift4 Payments in its $345 million initial public offering, $485 million follow-on offering and $495 million secondary transaction*
  • Mister Car Wash in its $562.5 million initial public offering*
  • Endeavor Group Holdings in its $511.3 million initial public offering and concurrent acquisition of the UFC*
  • The UFC in its $21.4 billion merger with WWE and creation of TKO Holdings*
  • Solo Stove in its $59.35 million follow-on offering*

*Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin, Adam was an associate at Latham & Watkins. He previously served as a Non-Commissioned Officer in the U.S. Army.

Credentials

Education

JD2016

University of Virginia School of Law

BSPolitical Science2013

Utah Valley University

Admissions

Bars

  • New York
  • Massachusetts

Recognition & Awards

Adam was included in the Legal 500 US 2024 for his work in Life Sciences.